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Abstract
Background: Chlamydia trachomatis is one of most commonly diagnosed sexually
transmitted infections worldwide but reports in the literature of an association
between genital chlamydia infection and adverse obstetric outcomes are
inconsistent.
Methods: A cohort of reproductive-aged women was created by linking Birth
Registrations and Electoral Roll records for women in Western Australia born from
1974-1995. This cohort was linked to both chlamydia testing records and the state
perinatal registry for data on preterm births and other adverse obstetric outcomes.
Associations between chlamydia testing, test positivity and adverse obstetric
outcomes were determined using multivariate logistic regression.
Findings: From 2001 to 2013, there were 101,558 women with a singleton birth of
which 3921 (3·9%) were classified as having a spontaneous preterm birth, 9762
(9·6%) a small-for-gestational-age baby and 682 (0·7%) a stillbirth. During their
pregnancy, 21,267 (20·9%) women had at least one chlamydia test record and 1365
(6·4%) of those tested were positive. Respective numbers of women tested and
positive prior to pregnancy were 19,157 (18·9%) and 1595 (8·3%). Among all women
with a test record, after adjusting for age, ethnicity, maternal smoking and history of
other infections, there was no significant association between a positive chlamydia
test and spontaneous preterm birth, small-for-gestational-age or stillbirth (adjusted
OR 1·08 (95%CI 0·91-1·28), 0·95 (0·85-1·07), and 0·93 (0·61-1·42) respectively).
Interpretation: A chlamydia infection diagnosed and treated either during or prior to
pregnancy does not substantially increase a woman’s risk of adverse obstetric
outcomes.
Funding: Australian National Health and Medical Research Council
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Introduction
Worldwide, chlamydia is one of the most common sexually transmissible infections
(STIs) with an estimated 131 million new cases annually; the majority diagnosed in
women of childbearing age.1 While genital infections are thought to contribute to the
incidence of adverse obstetric outcomes such as spontaneous preterm birth and
stillbirth,2 there are limited data regarding the role of chlamydia infections on these
outcomes. There are no published randomised controlled trials of the effects of
chlamydia screening in pregnancy on obstetric outcomes.3 Furthermore, randomised
placebo-controlled prevention trials of antibiotics (including azithromycin) given
during the antenatal period to high-risk women have found no effect on the rates of
preterm birth.4 Findings from observational studies have been inconsistent with
most,5-15 but not all,16-22 suggesting chlamydia infection increases the risk of preterm
birth. There is similar discordance in studies examining the effects of chlamydia
infection on birth weight and stillbirth.9,23

There are many possible explanations for the discrepancy in findings between
published observational studies. These include studies with small numbers of events
leading to random error; inconsistency in the type of chlamydia test used (serology,
culture or nucleic-acid amplification); variations in the outcome definition and
ascertainment; use of case-control designs where control populations may not be
well matched; inadequate control of potential confounders including other genital
tract infections, or other factors known to result in adverse obstetric outcomes such
as smoking during pregnancy; and the potential for publication bias. In this analysis
we use a large cohort of women with laboratory chlamydia testing and positivity
records and reliable ascertainment of outcomes to examine the effects of chlamydia
infection on the risk of spontaneous preterm birth, and other adverse birth outcomes.
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Methods
Study population and linkage
A cohort comprising women of reproductive age residing in the Australian state of
Western Australia (WA) was constructed by probabilistically linking two wholepopulation administrative datasets; Birth Registrations, which contain a record of all
children born and registered in WA from 1974 onwards, and the WA Electoral Roll.
Electoral enrolment is compulsory for Australian citizens with an estimated 92% of
the eligible population included on the roll in WA.24 Eligible women were all those
born between 1974 and 1995, derived from Birth Registrations or the 2014 WA
Electoral Roll.
This cohort was then linked to four datasets: laboratory testing data, the WA
Midwives Notification System, the WA Notifiable Infectious Diseases Database, and
the WA Hospital Morbidity Dataset. The laboratory data included all chlamydia
nucleic-acid amplification tests (NAAT) conducted between 1st January 2001 and
31st December 2013 at two large pathology laboratories providing services in the
state as well as tests for gonorrhoea and trichomonas. Data included the test type,
the date of test, and test result (positive, negative, or equivocal/undetermined).
Previous analysis has estimated that these two laboratories cover approximately
50% of all the chlamydia NAAT conducted in the state.25
The WA Midwives Notification System is a statutory database which receives
information from birth attendants about all births attended in WA where the infant has
a gestational age of 20 weeks or more, a birthweight of 400 grams or more, or if
gestation is unknown. Information available in this dataset includes details regarding
the birth such as labour onset, gestational age (based mostly on ultrasound or date
of last menstrual period), birth weight, infant sex, stillbirth, maternal demographics
and aspects of antenatal care and obstetric history. The WA Notifiable Infectious
Diseases Database contains a record of all notifiable conditions reported to the WA
Department of Health under statute including chlamydia, gonorrhoea, syphilis, and
viral hepatitis. Data obtained included the condition diagnosed and date of onset or
diagnosis. The WA Hospital Morbidity Dataset includes a record of all public and
private hospitalisations in the state. Data include the primary diagnosis (coded
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according to the International Classification of Diseases), any procedures and
admission and discharge dates.
Data linkage was conducted by the WA Data Linkage Branch using probabilistic
matching of personal identifiers such as name, date of birth, address, and sex.
Linkage accuracy using this process is high with an error rate estimated at 0.11%.26
All linkage was conducted independent of the study investigators and only deidentified data were provided to the researchers.
Outcome definitions
A woman was categorised as having a spontaneous preterm birth if she had a
delivery at <37 weeks gestation with spontaneous onset of labour. A small-forgestational-age baby was defined if the infant birth weight was less than the 10th
centile for gestational age by infant sex. Stillbirths (>20 weeks gestational age) were
identified in the Midwives Notification System.
Exposure to chlamydia testing and infection
Women were initially categorised according to their history of chlamydia testing in
relation to the pregnancy. The date of conception was calculated by subtracting the
number of weeks gestation from the date of birthing. Women were classified as
‘tested during pregnancy’ if the women had at least one chlamydia test during the
pregnancy, ‘tested prior to pregnancy’ if there was no record of a test during
pregnancy but at least one chlamydia test record dated prior to the pregnancy, and
‘no test record’ if there was no linked chlamydia test prior to the date of birthing.
As the risk of adverse outcomes could vary according to when a woman was tested,
analyses were then conducted to determine associations between chlamydia
positivity and each of the three outcomes taking test timing into account. Women
were classified into five categories: tested ‘negative’ during pregnancy, tested
‘positive’ during pregnancy, tested ‘negative’ prior to pregnancy, tested ‘positive’
prior to pregnancy and no test record with priority given to tests that occurred most
proximal to the date of birthing. A three category analysis was also investigated
examining the association with chlamydia positivity regardless of the timing of the
test (during or prior to pregnancy).
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Validity of chlamydia test result was assessed by comparing those testing positive
from the pathology data with chlamydia notifications from the WA Notifiable
Infectious Diseases Database.
Statistical analyses
Analyses were restricted to women in the cohort who had a first record of a singleton
birth (regardless of parity), between 2001 and 2012, in the Midwives Notification
System, and were resident in WA and aged ≥15 years at the time of giving birth.
Spontaneous preterm birth versus term birth, small-for-gestational-age versus not,
and stillbirth versus live birth were examined separately, however outcomes were not
mutually exclusive (e.g. stillbirths could also be classified as born preterm). Those
with missing outcome data were excluded from each analysis.
Multivariate logistic regression was used to determine the associations between
chlamydia testing and positivity and each of the three outcomes. All regression
analyses were initially adjusted for maternal age at delivery (in 5 year age groups),
area of residence (metropolitan, rural and remote, based on a Australian standard
statistical classification of postal codes), and socio-economic status (in tertiles based
on the Australian Bureau of Statistics Socio-Economic Indexes for Areas). We then
adjusted for other covariates based on known predictors of adverse obstetric
outcomes. These included: ethnicity (Caucasian, Aboriginal, other), smoking during
pregnancy (yes/no), other infections (hepatitis B/C or syphilis notification prior to the
delivery date); and based on linked pathology data, gonorrhoea and trichomonas (all
test negative, ≥1 test positive, no test record). Analyses were further adjusted for
parity (0, 1+), prior adverse obstetric outcomes (for each outcome we included a
variable indicating if the woman had an earlier birth record of that outcome),
hypertensive disease (yes/no), gestational and pre-existing diabetes (yes/no),
antepartum haemorrhage (yes/no), urinary tract infection (yes/no), and use of
assisted reproductive technologies (ART) (yes/no). Assessment of ART was based
on a hospital record in the year prior to conception with a code for procreative
management or assisted reproductive technologies in the diagnosis or procedure
fields. The most parsimonious model was reported in the results.
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As during the period of observation, chlamydia screening guidelines in Australia
recommended regular testing for young women and Aboriginal women, and
chlamydia testing patterns increased substantially after 2005,25 analyses were
repeated stratified by Aboriginality, age (<25 and ≥25 years), and year of giving birth
(≤2005, >2005). A sub-analysis was also conducted for preterm birth defined as <34
weeks gestation.
All analyses were performed using SAS software version 9.4 (SAS Institute Inc,
Cary, North Carolina). This study was approved by the Government of WA
Department of Health Human Research Ethics Committee (Ref #2012/73) and the
WA Aboriginal Health Ethics Committee (Ref 470).
Role of funding source
The funding source had no role in the study design, analysis, interpretation; nor in
the report writing and decision to submit for publication
Results
We identified 101,558 women with a first record of a singleton birth between 2001
and 2012 in the cohort. Of births that could be classified, 3921/101558 (3·9%) had a
spontaneous preterm birth, 9762/101371 (9·6%) births were small-for-gestationalage and 682/101,558 (0·7%) were stillbirths.
Table 1 shows women’s characteristics according to birth outcome. Generally,
women with each of the adverse obstetric outcomes shared similar characteristics.
They were younger, had lower socioeconomic status, were less likely to be resident
in a major city, and less likely to identify as Caucasian than those without the three
adverse outcomes. They were also more likely to have smoked during the
pregnancy, and to have been diagnosed with hepatitis C, syphilis, gonorrhoea and
trichomoniasis during or prior to the pregnancy.
Among the cohort, 21,267 (20·9%) were tested for chlamydia during their pregnancy
of whom 1365 (6·4%) were positive with the median first chlamydia test date at 14
weeks gestation; (IQR 8-23 weeks). Among the 19,157 (18·9%) women who only
had a chlamydia test record prior to their pregnancy, 1595 (8·3%) had a positive
result with the majority having their most recent test record over a year prior to
7

conception (median 1·7 years; IQR 0·6-3·5). The remaining 61,134 (60%) women
had no linked record of a chlamydia test prior to their date of delivery. Of women who
had a positive chlamydia test prior to delivery, 91.7% had a chlamydia notification in
the WA Notifiable Diseases Database during the corresponding period. Whilst of
those with only negative tests, and those with no test record, 3.2% and 1.4%
respectively had a chlamydia notification in the corresponding period.
Figure 1 shows the association between chlamydia testing and each birth outcome
evaluated. These results group those with both positive and negative tests together.
Compared to women who were tested for chlamydia during their pregnancy, women
who only had a record of testing prior to their pregnancy were significantly more
likely to have a spontaneous preterm birth (adjusted odds ratio [aOR] 1·15, 95%CI
1·04-1·27, p=0·008). The opposite was observed for small-for-gestational-age, with
women tested for chlamydia prior to pregnancy significantly less likely to have a
small-for-gestational-age baby than those who were tested during pregnancy (aOR
0·86, 95%CI 0·81-0·92, p<·0001). Women tested for chlamydia prior to pregnancy
were also substantially more likely to have a stillbirth than those tested for chlamydia
during pregnancy (aOR 1·71, 95%CI 1·35-2·17, p<·0001). For each of the three
outcomes there was no significant difference in risk between women with no test
record and women tested for chlamydia during their pregnancy in the fully adjusted
models.
Figure 2 shows the association between chlamydia positivity and each adverse
obstetric outcome. Among women tested for chlamydia during their pregnancy, 864
(4·5%) who were negative for chlamydia and 81 (6·2%) who were positive for
chlamydia had a spontaneous preterm birth. For women who only had a chlamydia
test record prior to their pregnancy, 696 (4·1%) test-negative women and 84 (5·5%)
test-positive women had a spontaneous preterm birth. In models adjusted for age,
region of residence and socioeconomic status, the risk of spontaneous preterm birth
in women testing positive versus negative for chlamydia approached, but did not
reach statistical significance. However, in the fully-adjusted model, there was no
significant association between chlamydia positivity and spontaneous preterm birth.
This was the case for women tested during pregnancy (aOR 1·00, 95%CI 0·79-1·27,
p=0·99) and remained regardless of the trimester during which testing occurred (first
trimester aOR 1·13, 95%CI 0·82-1·57, p=0·45; second/third trimester aOR 0·88,
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95%CI 0·62-1·25, p=0·48) and in women tested only prior to their pregnancy (aOR
1·12, 95%CI 0·89-1·42 p=0·33). The main factors resulting in attenuation of the risks
included adjustment for ethnicity, age and other infections (Appendix Table 1).
Among women tested during pregnancy, a higher percentage of women with a
positive chlamydia test had a small-for-gestational-age baby than those who tested
negative (17·1% vs 12·2%). Respective proportions among women only tested for
chlamydia prior to their pregnancy were 9·6% vs 8·6%. Similar to results for
spontaneous preterm birth, after adjustments, there were no significant differences in
the risk of a small-for-gestational-age baby by chlamydia positivity.
There were too few stillbirths to investigate the association with chlamydia positivity
stratified by test timing. Twenty-six (0·9%) women with a positive chlamydia test and
277 (0·7%) women who were negative for chlamydia had a stillbirth (Figure 2) and
there was no significant association between chlamydia positivity and stillbirth (aOR
0·93, 95%CI 0·61-1·42, p=0·74).
Analyses stratified by Aboriginality, age group and year of giving birth were
consistent with the main results for both spontaneous preterm birth and small-forgestational-age (Table 2). There was also no significant difference in the risk of
spontaneous preterm birth at <34 weeks by chlamydia positivity (see Appendix Table
2).
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Discussion
This large population-based cohort study analysed more than 20,000 women with
laboratory chlamydia testing data during pregnancy. With over 900 cases of
spontaneous pre-term birth and over 2500 small-for-gestational-age births, we found
no increase in the risk of having a spontaneous preterm birth or a small-forgestational-age baby among women with a positive chlamydia test. While there were
fewer cases, we also found no evidence to suggest a relationship of a positive
chlamydia test and stillbirth.
There has been one systematic review of 12 observational studies14 and a number of
other observational studies examining the association between chlamydia infection
and preterm birth with equivocal findings reported across studies. As a body of
evidence, interpreting these findings collectively is difficult for a number of reasons.
Firstly there is a lack of consistent outcome definition. Some studies have not
distinguished spontaneous preterm births from all other preterm births5,6,9,12,13,18,19,2123

and in many high-income countries a substantial proportion of preterm births are

planned (by labour induction or prelabour caesarean section) to manage obstetric
conditions such as hypertensive diseases.2 Similarly many studies report on low birth
weight without taking into account gestational age and therefore do not clearly
distinguish this outcome from preterm birth.7,8,18,23 Secondly, all of the larger studies
prior to this one do not have information on those who tested negative for
chlamydia.13,15,21,23 Thirdly some studies do not consider potential confounders such
as the presence of other genital infections, maternal smoking and ethnicity, and
therefore have been unable to account for these factors when quantifying
associations.8,9,12,22 Lack of consideration of such factors can lead to false positive
results. For example much chlamydia screening has focussed on young women with
multiple sexual partners.3 Younger age is strongly associated with spontaneous
preterm birth15 and young women with multiple sexual partners may be more likely to
take part in higher risk activities such as smoking in pregnancy that also increase the
risk of adverse obstetric outcomes; hence studies comparing positive women to
those not tested for chlamydia can be biased. Other differences that may also
contribute to the variation in findings include differences in study populations and
timing of testing during the pregnancy and the test type.
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This study had well-defined and reliably reported outcomes27 based on a statutory
perinatal birth register. We were able to make comparisons between women who
tested positive and negative for chlamydia and stratify by timing of tests in relation to
the pregnancy. We also took into account other important factors such as ethnicity,
maternal smoking and other infections. Furthermore, the cohort design, with
ascertainment of outcomes and exposures (chlamydia testing information) from
independent sources (perinatal register and pathology data respectively), reduced
the likelihood of biased reporting. On systematic searching of the literature, we
identified only four studies larger than this report to have examined the association
between chlamydia infection and preterm birth13,21,22 including one from our research
team.15 However, three lacked information on actual testing for chlamydia (ie. they
compared those with a positive chlamydia test to the rest of the population
regardless of whether they had been tested for chlamydia)13,15,21 and one casecontrol study only assessed chlamydia infection through presence of positive
serology (IgG) and found no association of chlamydia with preterm birth.22
Our findings of no increase in the risk of preterm birth with a chlamydia infection are
plausible and supported by results from some of the other observational
studies.11,17,19-22 The substantial attenuation of the risk of any adverse obstetric
outcome (including preterm birth) that we found after adjusting for other infections
and ethnicity support the notion that studies that reported positive associations
between chlamydia infection and preterm birth may be affected by residual
confounding. Further, while there are no reported trials of chlamydia screening of
women in pregnancy to reduce preterm birth,3 placebo-controlled trials of
prophylactic antibiotics (including azithromycin or erythromycin which are both
effective against chlamydia) given to women during the antenatal4 and
preconception period28 have shown no significant reduction in preterm birth rates.
These trial findings suggest that chlamydia is not a major causative organism in
preterm birth.
As we did not have treatment data, we assumed that women who tested positive
were treated for their chlamydia infection29 and hence our results should be
interpreted in this light. That is, the risk of spontaneous preterm birth is similar
11

between women who tested negative and those who tested positive who were
treated. We found that women who were tested for chlamydia prior to pregnancy, but
not during pregnancy, had a greater risk of preterm birth and stillbirth (aOR 1·15 and
1·71 respectively) than women who were tested during pregnancy. It is possible that
women who were only tested prior to pregnancy could have undiagnosed and hence
untreated chlamydia, or other genital infections, during the pregnancy and that the
untreated infection (ie. longer duration) may explain the observed increase in the risk
of adverse outcomes. Alternate explanations could be that these women were less
likely to access preventative antenatal care (including chlamydia screening), and it is
the reduced access to care that accounts for their higher risk.
We identified five observational studies that examined the association between
chlamydia and preterm birth and documented that the chlamydia infections were
untreated.5,6,16,17,30 Of these, four suggest an increase in risk of preterm birth but they
were all conducted prior to the year 2000 when nucleic-acid testing for chlamydia
became widespread. The only study17 that showed no increase in risk was also the
only one to have been conducted after 2000. Future studies of untreated chlamydia
infection in pregnancy are unlikely to be ethical however studies where routine postpartum testing for chlamydia (regardless of obstetric outcome) is conducted may
identify potentially untreated infections that had been present during pregnancy and
assist in establishing whether an untreated infection is itself a risk factor for preterm
birth.
While our linked pathology data did not include all tests conducted in the state,25 our
main comparisons are between women who tested positive for chlamydia and those
who tested negative. It is conceivable that some women may have been tested at
more than one laboratory but our data from the two labs show this was minimal with
no women tested at more than one of the labs during pregnancy and less than 10%
tested at more than one of the labs in the three years prior to pregnancy. Other
caveats on interpreting our findings include the lack of data on NAAT titres that may
correlate with severity of infection, and clinical information on whether infections
were symptomatic or not. Therefore we could not investigate whether more severe
infections themselves are associated with increased risk of adverse birth outcomes.
Nor were we able to examine factors such as effects of host genetic susceptibility.
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Overall our results suggest that a chlamydia infection diagnosed and treated either
during or prior to pregnancy does not increase a woman’s risk of spontaneous
preterm birth, small-for-gestational-age birth or stillbirth. These findings support the
continued screening of high risk women during pregnancy for chlamydia and they
should reassure women who have chlamydia diagnosed during pregnancy and
treated that there is no increased risk of serious adverse birth outcomes.
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Table 1 Participant characteristics according to birth outcome in Western Australian women born 1974-1995

N
% of all births
Demographics
Median age, years
(IQR)
% lower third socioeconomic status (N)
% resident in major city (N)
% Caucasian (N)
% Aboriginal (N)
% other ethnicity (N)

All births

Term

101558
100.0

94276
92.8

Preterm
Planned∞ Spontaneous
3361
3921
3.3
3.9

26.8
26.8
26.8
(23.0-29.8)
(23.0-29.8) (23.0-30.0)
35.2 (35722) 35.0 (33023) 35.3 (1187)
74.1 (75240) 74.2 (69917) 75.8 (2549)
83.1 (84385) 83.6 (78785) 78.3 (2630)
8.0 (8087)
7.5 (7062)
11.7 (392)
8.9 (9086)
8.9 (8429)
10.1 (339)

Antenatal factors
% smoked cigarettes during pregnancy (N) 17.4 (17673) 17.0 (16024) 19.8 (664)
% nulliparous (N)
59.3 (60184) 59.3 (55941) 57.2 (1922)
¥
% ART prior to conception (N)
1.3 (1282)
1.2 (1136)
2.4 (82)
Infections†
% hepatitis C (N)
0.7 (754)
0.7 (658)
1.1 (37)
% hepatitis B (N)
0.4 (370)
0.4 (342)
0.4 (12)
% syphilis (N)
0.1(122)
0.1 (107)
0.2 (*)
% gonorrhoea (N)
1.2(1200)
1.1 (1032)
2.1(72)
% trichomoniasis (N)
0.3 (348)
0.3 (294)
0.8 (26)
*small cell numbers suppressed

Small-for-gestational-age
No
Yes
91609
9762
90.4
9.6

26.2
(21.7-29.7)
38.6 (1513)
70.7 (2774)
75.7 (2970)
16.1 (633)
8.1 (318)

26.9
(23.1-29.9)
34.7(31755)
74.7 (68427)
84.4 (77288)
7.1 (6493)
8.5 (7828)

25.1 (985)
59.2 (2321)
1.6 (64)

16.0 (14617) 30.8 (3010)
59.2 (54189) 60.3 (5889)
1.3 (1179)
1.0 (98)

1.5 (59)
0.4 (16)
0.2(*)
2.5(96)
0.7 (28)

∞including labour inductions and prelabour caesarean sections
†diagnosed during or prior to pregnancy
¥Hospital record of access to assisted reproductive technology in year prior to conception (see methods)
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0.7 (626)
0.3 (301)
0.1 (90)
1.0(901)
0.3 (261)

Stillbirth
682
0.7

26.1
25.7
(21.7-29.5) (22.2-29.3)
39.8 (3885) 37.6 (256)
68.5 (6687) 67.9 (463)
71.3 (6962) 74.2 (506)
15.9 (1556) 15.4 (105)
12.7 (1244) 10.4 (71)

1.3 (125)
0.7 (67)
0.3 (32)
3.0(293)
0.9 (85)

25.7 (175)
58.9 (402)
1.3 (16)
1.2 (*)
0.3 (*)
0.4 (*)
1.4 (17)
0.3 (*)

Table 2 Association between chlamydia positivity and adverse obstetric outcomes by Aboriginality, age and year of giving
birth
N
Spontaneous preterm birth Chlamydia
Aboriginality
Non-Aboriginal
negative
31535
positive
1939
Aboriginal
negative
4558
positive
899
Age group (years)
<25
negative
14212
positive
1881
≥25
negative
21881
positive
957
Year of giving birth
2001-2005
negative
5827
positive
533
2006-2012
negative
30266
positive
2305
Small-for-gestational-age
Aboriginality
Non-Aboriginal
negative
32614
positive
2000
Aboriginal
negative
4785
positive
943
Age group (years)
<25
negative
14706
positive
1956

Heterogeneity
P value

n

Minimally adjusted* Fully adjusted+
OR (95%CI )
OR (95%CI )

1191
83
369
82

1.00
1.11 (0.89-1.40)
1.00
1.10 (0.86-1.42)

0.74
1.00
1.09 (0.87-1.38)
1.00
1.10 (0.85-1.42)

689
121
871
44

1.00
1.31 (1.07-1.60)
1.00
1.17 (0.85-1.59)

0.71
1.00
1.12 (0.92-1.37)
1.00
1.09 (0.80-1.49)

307
38
1253
127

1.00
1.24 (0.87-1.76)
1.00
1.22 (1.00-1.47)

0.45
1.00
1.06 (0.74-1.51)
1.00
1.10 (0.90-1.33)

2938
203
995
180

1.00
1.09 (0.94-1.27)
1.00
0.87 (0.73-1.05)

1.00
1.04 (0.90-1.21) 0.23
1.00
0.83 (0.69-1.00)

1874 1.00
285 1.12 (0.98-1.29)

1. 00
0.94 (0.81-1.08) 0.73
18

≥25
Year of giving birth
2001-2005
2006-2012

negative
positive

22693 2059 1.00
987
98 1.09 (0.88-1.35)

1.00
0.98 (0.79-1.22)

negative
positive
negative
positive

6047 817 1.00
550
93 1.12 (0.89-1.42)
31352 3116 1.00
2393 290 1.12 (0.98-1.27)

0.76
1.00
0.93 (0.73-1.19)
1.00
0.96 (0.84-1.10)

*Adjusted for age, area of

residence, and socioeconomic status;
+

Adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, other infections listed in table 1 and ethnicity
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Appendix Table 1 Association between chlamydia positivity (combining tested during and prior to pregnancy) and
adverse obstetric outcomes
c
OR (95%CI )

f
OR (95%CI )

g
OR (95%CI )

1.00
1.20 (1.01-1.41)

1.00
1.15 (0.97-1.36)

1.00
1.08 (0.91-1.28)

1.00
1.08 (0.91-1.28)

1.00
1.11 (0.99-1.25)

1.00
1.06 (0.95-1.19)

1.00
1.00 (0.89-1.13)

1.00
0.95 (0.85-1.07)

1.00
0.95 (0.85-1.07)

1.00
1.05 (0.70-1.59)

1.00
1.03 (0.69-1.54)

1.00
0.98 (0.65-1.49)

1.00
0.93 (0.61-1.42)

1.00
0.93 (0.62-1.42)

1.00
1.24 (1.05-1.47)

1.00
1.23 (1.04-1.45)

1.00
1.22 (1.04-1.45)

Small for gestational age
negative
1.00
positive
1.27 (1.14-1.43)

1.00
1.14 (1.02-1.28)

1.00
1.12 (1.00-1.25)

Stillbirth
negative
positive

1.00
1.08 (0.72-1.62)

1.00
1.06 (0.70-1.59)

1.00
1.19 (0.80-1.79)

b
OR (95%CI )

d
OR (95%CI )

a
OR (95%CI )
Spontaneous preterm birth
negative
1.00
positive
1.37 (1.16-1.61)

e
OR (95%CI )

h
OR (95%CI )

Models in bold type were reported in Figure 2 in main report
Model a: Unadjusted
Model b: Adjusted for age
Model c: Adjusted for age, and area of residence
Model d: Adjusted for age, area of residence, and socioeconomic status
Model e: Adjusted for age, area of residence, socioeconomic status, and smoked during pregnancy
Model f: Adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, and other infections listed in table 1
Model g: Adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, other infections listed in table 1 and ethnicity
Model h: Adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, other infections listed in table 1, ethnicity and use of
assisted reproductive technologies.
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Figure 1: Association between chlamydia testing history an adverse obstetric
outcomes

Minimally adjusted model adjusted for age, area of residence, and socioeconomic status
Fully adjusted model adjusted for age, area of residence, socioeconomic status, smoked during
pregnancy, other infections listed in table 1 and ethnicity
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Figure 2: Association between chlamydia positivity and adverse obstetric
outcomes

Women with no test record were included in the analysis but data not shown
Minimally adjusted model adjusted for age, area of residence, and socioeconomic status
Fully adjusted model adjusted for age, area of residence, socioeconomic status, smoked during
pregnancy, other infections listed in table 1 and ethnicity
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